| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b4d6e274df7b9b6289b08e5f0114d84 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 |
| filingDate |
2019-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd633472202e7ecf08bb550f0bb23688
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19a6aa51e3eb03b2747466d91ed8e427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc68d756d2cff5cea9d6b37b4836b515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25f07206348abd41d793b47b6e56d724 |
| publicationDate |
2020-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-112074538-A |
| titleOfInvention |
Antibodies and bispecific antigen binding molecules that bind HER2 and/or APLP2, their conjugates and uses |
| abstract |
A protein called human epidermal growth factor 2 (HER2) is expressed in breast cancer cells, and its expression is associated with aggressive tumor growth. The present invention provides novel full-length human (IgG) antibodies that bind to human HER2 (monospecific antibody) or APLP2 (monospecific antibody). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both HER2 and APLP2 and mediate the internalization and degradation of HER2 via the APLP2 complex in the presence of a HER2-expressing tumor . Bispecific antigen-binding molecules and ADCs comprising a first antigen-binding domain that specifically binds human APLP2 and a second antigen-binding domain that specifically binds human HER2 are described. The described bispecific ADCs are capable of inhibiting the growth of certain HER2-expressing tumors and are useful in the treatment of breast cancer and in conditions for which targeting of therapeutic agents to HER2-expressing tumor cells is desirable and/or therapeutically beneficial. For example, the bispecific antibodies of the invention can be used to treat breast cancer, including breast cancers with the IHC2 + class. The present invention also includes anti-HER2 antibody drug conjugates that inhibit tumor growth in vivo. |
| priorityDate |
2018-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |